Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610
28 Mai 2020 - 6:00PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, will host a
virtual analyst/investor event and conference call on June 12 at
8:00 AM EDT to discuss the data from three posters on the MANIFEST
clinical trial for CPI-0610 being presented at the European
Hematology Association meeting.
The agenda of the event will include:
- An overview of myelofibrosis (MF) and the potential impact of
Constellation’s BET inhibitor CPI-0610 in treating
MF
- A review of the data from the MANIFEST clinical trial presented
in the EHA posters
- A live question-and-answer session
The event will be webcast live and can be accessed on the
Investor Relations section of Constellation’s website
at http://ir.constellationpharma.com/events-and-presentations/events.
To participate in the live question-and-answer session, please dial
(877) 473-2077 (domestic) or (661) 378-9662 (international) and
refer to conference ID 6275774.
About MANIFEST
MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in
patients with myelofibrosis (MF), a rare cancer of the bone marrow
that disrupts the body’s normal production of blood cells.
Constellation is evaluating CPI-0610 in combination with
ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a
primary endpoint of the proportion of patients with a ≥35% spleen
volume reduction from baseline (SVR35) after 24 weeks of treatment.
Constellation is also evaluating CPI-0610, either as a monotherapy
in patients who are resistant to, intolerant of, or ineligible for
ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy
in combination with ruxolitinib in patients with a sub-optimal
response to ruxolitinib or MF progression (Arm 2). Patients in Arms
1 and 2 are being stratified based on TD status. The primary
endpoint for the patients in cohorts 1A and 2A, who were TD at
baseline, is conversion to TI for 12 consecutive weeks. The primary
endpoint for the patients in cohorts 1B and 2B, who were not TD at
baseline, is the proportion of patients with a ≥35% spleen volume
reduction from baseline after 24 weeks of treatment.
About Constellation
Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the BET
inhibitor CPI-0610 for the treatment of myelofibrosis as well as
the EZH2 inhibitors CPI-1205 and CPI0209 for the treatment of
metastatic castration-resistant prostate cancer and other
cancers. The Company is also applying its broad research and
development capabilities to explore other novel targets that
directly and indirectly impact gene expression to fuel a
sustainable pipeline of innovative small-molecule product
candidates.
Contact
Kia Khaleghpour, PhDVice President, Investor Relations and
CommunicationsConstellation Pharmaceuticals+1
617-844-6859kia.khaleghpour@constellationpharma.com
Ronald Aldridge Investor RelationsConstellation
Pharmaceuticals +1
617-714-0539ron.aldridge@constellationpharma.com
Lauren Arnold Media Relations MacDougall Biomedical
Communications +1 781-235-3060 larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Constellation Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur